14 September 2018
A new report by visiongain forecasts the world market for colorectal cancer drugs will reach $10.75 billion in 2019. That revenue prediction and others appear in Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025, published in November 2015. Visiongain is a business information publisher and consultancy in London, UK.
That new analysis predicts the global colorectal cancer drugs market will grow at a CAGR of 5% from 2014 to 2019. Overall world revenue expansion will be stimulated by rising incidence of cancer in developing countries, widening access to healthcare, shifts towards personalised medicine and drug development that gives more options and better treatments.
Sandra Wenas, a pharmaceutical industry analyst in visiongain, said: “The colorectal cancer drugs market will continue to expand at a steady pace, owing to an increase in the global incidence of cancer. Treatment options will become more targeted, and tailored to individual patients, leading to the need for better diagnostic techniques. And, as developed national markets mature, emerging markets will continue to drive the growth of the industry, as these countries put more money and resources into healthcare and research.”
Most of the blockbuster drugs driving the colorectal cancer market have or are about to reach patent expiry. Despite the large number of drug candidates in the R&D pipeline, only a few appear to hold great promise. The future of the colorectal cancer drugs market depends on the success of those drug candidates and further innovation from pharmaceutical companies.
Visiongain’s new investigation shows revenue forecasts to 2025 at overall world market, product and geographical level.
That study forecasts revenues from 2015 to 2025 for the top nine colorectal cancer drugs on the market in 2015. Those products include Avastin, Erbitux, Xeloda and Vectibix.
The work also profiles companies and discusses products in research and development. That analysis explains activities and prospects of organisations such as Roche, BMS, Sanofi, Eli Lilly and Amgen. It includes two interviews with authorities in the pharmaceuticals industry.
In addition, the study explains trends and shows revenue forecasts to 2025 for these regions:
• United States • Japan • European Union • APAC • Rest of the World.
Visiongain predicts the APAC group will show the fastest growth and account for 19% of the world colorectal cancer drugs market for revenues in 2025.
Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025 adds to visiongain’s range of reports on industries and markets in healthcare. Those studies cover pharmaceuticals, biotechnologies, medical devices, diagnostic tests and outsourced services.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.